DNA encoding IL-2 fusion proteins with modulated selectivity
US7888071B2 · kind B2 · utility
45Cited by
118References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2008 |
| Grant date | Feb 15, 2011 |
| Priority date | — |
| Expiry date | Feb 19, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.